AbbVie presented the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 data of Rinvoq in patients with psoriatic arthritis. Rinvoq demonstrated better clinical response related to the axial movements compared to placebo at week 24.
Axial response improvement is determined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4 and BASDAI Question 2 ≥4 at baseline. In SELECT-PsA 1 study, Rinvoq demonstrated improvements in BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS) endpoints versus adalimumab and placebo.
Also read: Top 10 pharma companies by revenues in 2021
AbbVie presented KEEPsAKE 1 and KEEPsAKE 2 trial results of Skyrizi in patients with psoriatic arthritis (PsA). The company presented the 24-week integrated results comparing Skyrizi versus placebo.
Skyrizi demonstrated improvement in the signs and symptoms of PsA compared to placebo; the ACR20 response was 55.5% versus 31.3% in the placebo arm. PASI90 was achieved in 53.2% of patients versus 10% in patients on placebo. Further, the drug showed improvement in the patient-reported outcomes.
Janssen presented the DISCOVER-1 and DISCOVER-2 clinical trials, demonstrating the superiority of Tremfya versus placebo. Tremfya inhibited radiographic progression and showed improvements in axial symptoms, pain, and other symptoms in patients with psoriatic arthritis.
Novartis presented the data of Cosentyx in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA). The risk of flares was reduced by 72% in both the patient population of ERA and JPsA.
The company presented the Phase III JUNIPERA study, in which Cosentyx reduced the risk of flares by 72%. After week one, 30% of patients on Cosentyx showed improvement, and after 12 weeks, 90% achieved JIA ACR 30.